相关实验视频

Updated: Jun 18, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

增加表达的梅瓦诺酸通路相关的酶在 ангиотензинII诱导的腹腔大动脉动脉瘤

Yajun Liu¹, Jiangjie Lou², Yingzheng Weng¹

¹Department of Medicine, The Second College of Clinical Medicine, Zhejiang Chinese Medical University.

International heart journal

|July 31, 2024

概括

腹腔大动脉瘤 (AAA) 的进展涉及增加的美酸通路 (MVA) 酶表达和小的GTP结合蛋白激活. 这项研究将MVA通路变化与AAA发育联系在由 ангиотензинII诱导的模型中.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
生物化学生物化学

背景情况:

腹腔大动脉瘤 (AAA) 是一种危及生命的疾病,死亡率高.
梅瓦酸盐 (MVA) 途径在AAA病变发生过程中的作用尚不清楚.
心血管疾病通常在MVA通路中表现出异常.

研究的目的:

为了研究MVA相关的酶表达的变化在 ангиотензинII (AngII) 诱导的AAA的进展期间.
确定MVA路径对AAA发展的影响.

主要方法:

对动物进行5天和28天的 ангиотензин II (Ang II) 输注,以诱导AAA.
生物化学和组织学分析以评估AAA特征.
西方斑点和单细胞RNA测序 (scRNA-seq) 用于分析与MVA相关的酶表达.

主要成果:

持续28天的Ang II输液导致大动脉显著扩张和动脉重塑.
与MVA相关的酶表达和小GTP结合蛋白激活在Ang II诱导后显著增加.
在Ang II28天组中,scRNA-seq证实了更高的关键MVA酶基因表达.
即使在早期 (5天) 的Ang II输液阶段,也观察到酶表达和G蛋白活性升高.

结论:

Ang II诱导的腹腔大动脉扩张和重塑与关键MVA通路酶的改变表达有关.
在AAA开发的早期阶段,MVA途径与AAA发展有关.
对MVA途径在AAA中的作用进行进一步的研究是有必要的.

关键词:

3-基-3-甲基格卢塔利尔辅酶A减少酶法尔尼西尔二酸盐合成酶的使用.一个单细胞RNA-seqq.小型GTPases是什么意思

更多相关视频

Ultrasound Imaging of the Thoracic and Abdominal Aorta in Mice to Determine Aneurysm Dimensions

Ultrasound Imaging of the Thoracic and Abdominal Aorta in Mice to Determine Aneurysm Dimensions

Published on: March 8, 2019

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model

Published on: November 18, 2022

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...